Literature DB >> 16299033

Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection.

D A Price1, M F Bassendine, S M Norris, C Golding, G L Toms, M L Schmid, C M Morris, A D Burt, P T Donaldson.   

Abstract

BACKGROUND: Host genetic factors may significantly influence the ability to clear hepatitis C virus (HCV) following infection. HCV is associated with very low density lipoproteins (VLDL) and low density lipoproteins (LDL) in the host's circulation. Apolipoprotein E (APOE) is found in VLDL and binds to potential receptors involved in HCV entry into cells, the LDL receptor, and the scavenger receptor protein SR-B1. The APOE gene is polymorphic with three alleles coding for three isoforms: Apo-epsilon2, Apo-epsilon3, and Apo-epsilon4. The aim of this study was to assess if these functional polymorphisms determine disease outcome in HCV infected individuals.
METHODS: The APOE genotype was determined in 420 Northern European patients with evidence of exposure to HCV. Genotype and allele distribution were compared with those of 288 healthy controls and progression of liver disease and viral clearance were analysed according to APOE allele status.
RESULTS: The APOE*E2 and APOE*E4 alleles were both associated with a reduced likelihood of chronic infection (odds ratio (OR) 0.39 (95% confidence interval (CI) 0.211-0.728), p = 0.003; and OR 0.6 (95% CI 0.38-0.96), p = 0.032) and there was a notable absence of the E2E2 genotype in the HCV antibody positive group compared with the control population (p = 0.0067). Overall the genotypes carrying the E2 allele (E2,E3 and E2,E4) were associated with the equivalent of a 3-5-fold reduction in the risk of chronic HCV infection (genotype relative risk 0.36 and 0.20, respectively).
CONCLUSION: This study indicates that functional APOE gene polymorphisms may be a determinant of outcome in HCV infection. We hypothesise that the E2 allele may protect against viral persistence via defective binding of HCV lipoviral particles to the cellular receptors involved in entry of these infectious particles.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16299033      PMCID: PMC1856106          DOI: 10.1136/gut.2005.079905

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  43 in total

Review 1.  Problems of reporting genetic associations with complex outcomes.

Authors:  Helen M Colhoun; Paul M McKeigue; George Davey Smith
Journal:  Lancet       Date:  2003-03-08       Impact factor: 79.321

Review 2.  CCR5 and HIV infection.

Authors:  Cédric Blanpain; Frédérick Libert; Gilbert Vassart; Marc Parmentier
Journal:  Receptors Channels       Date:  2002

Review 3.  Cerebral dysfunction in chronic hepatitis C infection.

Authors:  D M Forton; S D Taylor-Robinson; H C Thomas
Journal:  J Viral Hepat       Date:  2003-03       Impact factor: 3.728

4.  Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.

Authors:  Birke Bartosch; Alessandra Vitelli; Christelle Granier; Caroline Goujon; Jean Dubuisson; Simona Pascale; Elisa Scarselli; Riccardo Cortese; Alfredo Nicosia; François-Loïc Cosset
Journal:  J Biol Chem       Date:  2003-08-11       Impact factor: 5.157

5.  Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus.

Authors:  Matthew A Wozniak; Ruth F Itzhaki; E Brian Faragher; Martin W James; Steven D Ryder; William L Irving
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

6.  Genomic analysis of the host response to hepatitis C virus infection.

Authors:  Andrew I Su; John P Pezacki; Lisa Wodicka; Amy D Brideau; Lubica Supekova; Robert Thimme; Stefan Wieland; Jens Bukh; Robert H Purcell; Peter G Schultz; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-19       Impact factor: 11.205

7.  Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

Authors:  Thierry Poynard; Vlad Ratziu; John McHutchison; Michael Manns; Zachary Goodman; Stefan Zeuzem; Zobair Younossi; Janice Albrecht
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

Review 8.  Viral hepatitis C.

Authors:  Thierry Poynard; Man-Fung Yuen; Vlad Ratziu; Ching Lung Lai
Journal:  Lancet       Date:  2003-12-20       Impact factor: 79.321

9.  Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.

Authors:  Jean Michel Petit; Muriel Benichou; Laurence Duvillard; Valerie Jooste; Jean Baptiste Bour; Anne Minello; Bruno Verges; Jean Marcel Brun; Philippe Gambert; Patrick Hillon
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

10.  The role of human and mouse hepatic scavenger receptor class B type I (SR-BI) in the selective uptake of low-density lipoprotein-cholesteryl esters.

Authors:  David Rhainds; Mathieu Brodeur; Jany Lapointe; Daniel Charpentier; Louise Falstrault; Louise Brissette
Journal:  Biochemistry       Date:  2003-06-24       Impact factor: 3.162

View more
  39 in total

1.  Do high lipids help clearance of hepatitis C?

Authors:  Stephen Ryder
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

Review 2.  Chronic hepatitis C virus infection and lipoprotein metabolism.

Authors:  Yoshio Aizawa; Nobuyoshi Seki; Tomohisa Nagano; Hiroshi Abe
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

3.  Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins.

Authors:  Olivier Diaz; François Delers; Marianne Maynard; Sylvie Demignot; Fabien Zoulim; Jean Chambaz; Christian Trépo; Vincent Lotteau; Patrice André
Journal:  J Gen Virol       Date:  2006-10       Impact factor: 3.891

4.  Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection.

Authors:  Ornit Chiba-Falek; Colton Linnertz; John Guyton; Stephen D Gardner; Allen D Roses; Jeanette J McCarthy; Keyur Patel
Journal:  Hum Genet       Date:  2012-08-17       Impact factor: 4.132

5.  Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression.

Authors:  Trevor D Burt; Brian K Agan; Vincent C Marconi; Weijing He; Hemant Kulkarni; Jeffrey E Mold; Marielle Cavrois; Yadong Huang; Robert W Mahley; Matthew J Dolan; Joseph M McCune; Sunil K Ahuja
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-18       Impact factor: 11.205

6.  Hyperlipidemia offers protection against Leishmania donovani infection: role of membrane cholesterol.

Authors:  June Ghosh; Shantanabha Das; Rajan Guha; Debopam Ghosh; Kshudiram Naskar; Anjan Das; Syamal Roy
Journal:  J Lipid Res       Date:  2012-10-10       Impact factor: 5.922

7.  Identification of microRNAs involved in dexamethasone-induced muscle atrophy.

Authors:  He Shen; Teng Liu; Liangliang Fu; Shuhong Zhao; Bin Fan; Jianhua Cao; Xinyun Li
Journal:  Mol Cell Biochem       Date:  2013-05-29       Impact factor: 3.396

8.  Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture.

Authors:  Kyung-Soo Chang; Jieyun Jiang; Zhaohui Cai; Guangxiang Luo
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

9.  Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis.

Authors:  Ali Sazci; Gurler Akpinar; Cem Aygun; Emel Ergul; Omer Senturk; Sadettin Hulagu
Journal:  Dig Dis Sci       Date:  2008-05-09       Impact factor: 3.199

Review 10.  Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review.

Authors:  Inga Kuhlmann; Anne Marie Minihane; Patricia Huebbe; Almut Nebel; Gerald Rimbach
Journal:  Lipids Health Dis       Date:  2010-01-28       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.